NCT05442684View on ClinicalTrials.gov

A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2022

Primary Completion Date

March 30, 2023

Study Completion Date

June 30, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector)

Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O

BIOLOGICAL

Bivalent Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation

Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of Ad5-nCoV/O-IH

BIOLOGICAL

mRNA-based COVID-19 vaccine

Subjects who have completed the primary mRNA vaccine immunizations and the 1st booster AZD1222 immunization for more than 6 months will be randomized to receive a 2nd booster dose of mRNA-based COVID-19 vaccine

Sponsors
All Listed Sponsors
lead

CanSino Biologics Inc.

INDUSTRY

NCT05442684 - A Study to Evaluate the Safety and Immunogenicity of Ad5-vector Based Vaccine Against Coronavirus Variants in Adults (≥18 Years) Immunized With 2 Doses of mRNA Vaccines Plus One Dose of Booster AZD1222 Vaccine | Biotech Hunter | Biotech Hunter